Zoetis Inc. (NYSE:ZTS) Shares Purchased by RWA Wealth Partners LLC

RWA Wealth Partners LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 358.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,645 shares of the company’s stock after purchasing an additional 8,324 shares during the period. RWA Wealth Partners LLC’s holdings in Zoetis were worth $2,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC raised its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the period. Moisand Fitzgerald Tamayo LLC raised its position in Zoetis by 105.5% during the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after acquiring an additional 96 shares during the period. Independence Bank of Kentucky raised its position in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after acquiring an additional 130 shares during the period. Ramirez Asset Management Inc. acquired a new position in Zoetis during the third quarter worth $35,000. Finally, First Financial Corp IN raised its position in Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 2.8 %

Shares of ZTS opened at $149.56 on Wednesday. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm has a 50-day moving average price of $173.78 and a 200 day moving average price of $179.78. The firm has a market capitalization of $68.40 billion, a P/E ratio of 29.50, a P/E/G ratio of 2.22 and a beta of 0.85.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 EPS. Sell-side analysts forecast that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.16%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last 90 days. 0.15% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Barclays reduced their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. The Goldman Sachs Group increased their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $218.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.